WGA makes cutting-edge genomics technologies and cancer support services accessible to insurance companies, brokers, employers and employees in a responsible, easy and cost-effective manner. WGA’s solutions enable insurance policyholders to make informed health choices by facilitating the development of personalized policies based on a user’s specific genome profile. For brokers, WGA offers extensive knowledge on genomic products and services, so that they can provide their customers with robust and competitive employee benefits packages. At the same time, employers can inspire their workforce to access the benefits of genomic profiling and enhance the health, wellness, and longevity of employees with WGA’s offerings. “Leveraging three decades of our industry expertise, we develop innovative benefits and financial strategies that accelerate access to genomic solutions, and ensure the effective management of health risks,” says Rowe.
At the core of WGA’s superior delivery of cutting-edge genomics and oncology solutions and services is the company’s passionate and dedicated team, which recognizes the ever-evolving healthcare world and ensures equivalent access to genomic technologies.
Apart from offering ground-breaking genomic solutions, WGA also provides tech-based tools to optimize the overall delivery of care. For instance, the company has integrated a medical records platform into its offerings to optimize the movement of employee health information between doctors and other care providers. “By helping patients understand the landscape and putting them in control of their data, we empower them to take a more participatory role in their treatment planning, which has been shown to be hugely beneficial”. says Rowe.
“The use of medical data management is just one example of how we leverage technology to facilitate better interoperability between patients and caregivers and enable access to our services in a very convenient way,” adds Rowe.
Since its inception, WGA’s focus has been on improving health risk management for as many lives as possible through the delivery of innovative genomic technologies. In order to achieve this, the company geared its business model toward a mass-scale distribution model for its services. Moreover, with its extensive network of oncology specialists, genomic scientists, and leading cancer management companies worldwide, WGA ensures the efficient delivery and implementation of leading-edge genomic technology around the globe.
Looking ahead, WGA plans to spearhead the charge toward the pre-emptive detection of health risks through the development of new genomic technology applications for the evolving healthcare industry. From a geographical perspective, the company is reviewing multiple locations beyond the U.S. with a vision to offer its services to more people worldwide. To conclude, Rowe shares his vision of the future, which states, “WGA will continue to enhance the delivery of innovative genomic technology to assist businesses around the world in effectively managing health risks.”